MedTrace Logo

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00832494 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2009-01-30

No results posted yet for this study

Summary

This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.

Conditions

Interventions

DRUG

DMXAA in combination with carboplatin and paclitaxel

Administered every 21 days

Sponsors & Collaborators

  • Antisoma Research

    lead INDUSTRY

Principal Investigators

  • Mark McKeage · Auckland Medical School, Auckland, New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2007-08-31
Completion
2007-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832494 on ClinicalTrials.gov